Investigational drug · Phase 2
KN035
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
20
Any phase or sponsor naming "KN035"
First trial start
2018
Aug 22, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KN035", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "KN035" as an intervention, largest first.
- Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTCPivotal-lookingCompleted
3D Medicines (Sichuan) Co., Ltd.Industry
NCT03478488 · 472 participants · Start Apr 16, 2018 · Primary completion Sep 10, 2024
Drug: KN035 plus Gemcitabine & oxaliplatin; Gemcitabine & oxaliplatin · For: Biliary Tract Neoplasms
Sites: Nanjing, China
3D Medicines (Sichuan) Co., Ltd.Industry
NCT03101488 · 287 participants · Start Mar 21, 2017 · Primary completion Sep 2, 2019
Drug: KN035 · For: Solid Tumors
Sites: Changsha, China; Suzhou, China; Shanghai, China · 4 sites in all
- ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaPivotal-lookingStatus unknown
Tracon Pharmaceuticals Inc.Industry
NCT04480502 · 207 participants · Start Dec 9, 2020 · Primary completion Oct 2024
Drug: Envafolimab; Ipilimumab · For: Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma
Sites: Tucson, Arizona; Los Angeles, California; Santa Monica, California · 30 sites in all
- KN035 for dMMR/MSI-H Advanced Solid TumorsActive, not recruiting
3D Medicines (Sichuan) Co., Ltd.Industry
NCT03667170 · 188 participants · Start Aug 22, 2018 · Primary completion Dec 30, 2026
Drug: KN035 · For: Solid Tumor
Sites: Hefei, China; Beijing, China; Fuzhou, China · 27 sites in all
3D Medicines (Sichuan) Co., Ltd.Industry
NCT05024214 · 170 participants (planned) · Start Nov 15, 2021 · Primary completion Dec 2026
Drug: Lenvatinib + Envafolimab; Sunitinib · For: Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma and 1 more
Sites: Bengbu, China; Beijing, China; Fuzhou, China · 23 sites in all
3D Medicines (Sichuan) Co., Ltd.Industry
NCT04891198 · 126 participants (planned) · Start Aug 6, 2021 · Primary completion Aug 30, 2027
Drug: Envafolimab · For: Solid Tumor
Sites: Beijing, China
- Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal CancerNot yet recruiting
池畔Academic, hospital or other
NCT05969847 · 72 participants (planned) · Start Aug 15, 2023 · Primary completion Dec 31, 2027
Drug: CAPOX; Envafolimab · For: Rectal Cancer
Sites: Fuzhou, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT04034823 · 59 participants (planned) · Start Sep 1, 2019 · Primary completion Jan 1, 2021
Drug: KN035; Trastuzumab and 1 more · For: HER2-positive Breast Cancer
- A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular CarcinomaNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06143579 · 48 participants (planned) · Start Dec 15, 2023 · Primary completion Mar 3, 2025
Drug: FOLFOX-HAIC+Lenvatinib+Envolizumab · For: Potentially Resectable Hepatocellular Carcinoma
- Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical CancerNot yet recruiting
Chongqing University Cancer HospitalAcademic, hospital or other
NCT05799469 · 36 participants (planned) · Start May 1, 2023 · Primary completion May 31, 2027
Drug: Envafolimab; Cisplatin · For: Locally Advanced Cervical Cancer
Sites: Chongqing, China
Newest research
PubMed records naming it or its code names, newest first.
- Production of isotope-labeled nanobody KN035 in Pichia pastoris yields native-like conformation and PD-L1 binding activity comparable to KN035 expressed in mammalian cells.
Ren P, Jiang M, Wang S · Magn Reson Lett 2026
- MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies.
Wei Y, Zhou P, Weng N, et al. · ACS Biomater Sci Eng 2026
- A Preclinical Study of [64Cu]Cu-NOTA-KN035 for Molecular Imaging of PD-L1 in Tumors.
Xu Y, Hua Y, Liu X, et al. · Mol Pharm 2026
- A Dually Nanobody-Engineered Milk-Derived Extracellular Vesicle Nanomedicine Targeting Tumour-Associated Macrophages and Cancer Cells for Cancer Therapy.
Liu Z, Chen Y, Cao Y, et al. · J Extracell Vesicles 2026
- PD-L1 Blockade with Biodegradable Envafolimab-Loaded Microspheres Synergizes with Transarterial Chemoembolization to Overcome Myeloid-Derived Suppressor Cell-Driven Immune Escape in Hepatocellular Carcinoma.
Liu H, Huang J, Wang Z, et al. · ACS Appl Mater Interfaces 2026
- Intelligent bacterial platform induces programmed death-ligand 1 lysosomal degradation to enhance antitumor immunity.
He S, Zhao S, Luo X, et al. · Int J Biol Macromol 2025
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.